ES2548238T3 - Formulaciones antagonistas de VEGF - Google Patents

Formulaciones antagonistas de VEGF Download PDF

Info

Publication number
ES2548238T3
ES2548238T3 ES06748594.6T ES06748594T ES2548238T3 ES 2548238 T3 ES2548238 T3 ES 2548238T3 ES 06748594 T ES06748594 T ES 06748594T ES 2548238 T3 ES2548238 T3 ES 2548238T3
Authority
ES
Spain
Prior art keywords
vegf antagonist
vegf
vegf receptor
receptor
antagonist formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06748594.6T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Dix
Kelly Frye
Susan Kautz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548238(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2548238T3 publication Critical patent/ES2548238T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES06748594.6T 2005-03-25 2006-03-22 Formulaciones antagonistas de VEGF Active ES2548238T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66512505P 2005-03-25 2005-03-25
US665125P 2005-03-25
PCT/US2006/010600 WO2006104852A2 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations

Publications (1)

Publication Number Publication Date
ES2548238T3 true ES2548238T3 (es) 2015-10-15

Family

ID=36678320

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13152402.7T Active ES2633574T3 (es) 2005-03-25 2006-03-22 Formulaciones de antagonistas de VEGF
ES06748594.6T Active ES2548238T3 (es) 2005-03-25 2006-03-22 Formulaciones antagonistas de VEGF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13152402.7T Active ES2633574T3 (es) 2005-03-25 2006-03-22 Formulaciones de antagonistas de VEGF

Country Status (19)

Country Link
US (16) US20060217311A1 (enExample)
EP (3) EP2586459B1 (enExample)
JP (2) JP5376573B2 (enExample)
KR (1) KR101327270B1 (enExample)
CN (2) CN102614134B (enExample)
AU (1) AU2006229930C1 (enExample)
CA (3) CA2598711C (enExample)
CY (2) CY1116980T1 (enExample)
DK (2) DK2586459T3 (enExample)
ES (2) ES2633574T3 (enExample)
HU (2) HUE034109T2 (enExample)
IL (2) IL185606A (enExample)
LT (1) LT2586459T (enExample)
NZ (1) NZ560713A (enExample)
PL (2) PL1861116T3 (enExample)
PT (2) PT1861116E (enExample)
SI (2) SI2586459T1 (enExample)
WO (1) WO2006104852A2 (enExample)
ZA (1) ZA200708845B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
AU2012202859C1 (en) * 2006-06-16 2025-08-07 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
CN102552875B (zh) * 2010-12-09 2015-05-20 上海国健生物技术研究院 一种双功能vegf受体融合蛋白制剂
CA2824422A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CA2833144C (en) * 2011-04-14 2020-09-29 The Regents Of The University Of California Multilayer thin film drug delivery device and methods of making and using the same
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
NZ730271A (en) * 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
KR20150038297A (ko) * 2012-08-02 2015-04-08 사노피 아플리베르셉트 또는 지브-아플리베르셉트를 포함하는 제조 물품
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN103110105A (zh) * 2012-11-14 2013-05-22 江苏江山制药有限公司 食品添加剂无糖维生素c钠盐颗粒的生产方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN104940926B (zh) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
HRP20231379T1 (hr) 2015-12-03 2024-02-16 Regeneron Pharmaceuticals, Inc. Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10576128B2 (en) * 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2018068012A1 (en) 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
JP7116059B2 (ja) * 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
USD849856S1 (en) 2017-06-28 2019-05-28 Jumpsport, Inc. Standing platform
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CA3082899A1 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CA3189025A1 (en) * 2017-12-22 2019-06-27 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US11667702B2 (en) 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
IL318714A (en) * 2018-05-10 2025-03-01 Regeneron Pharma Formulations that include high concentrations of VEGF receptor fusion protein
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
MY190623A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
KR102337471B1 (ko) * 2019-12-23 2021-12-09 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
KR20220015976A (ko) * 2020-07-31 2022-02-08 (주)셀트리온 안정한 약제학적 제제
CN120204358A (zh) * 2023-12-27 2025-06-27 成都康弘生物科技有限公司 一种含有抗vegf的融合蛋白的药物组合物
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JPH10273450A (ja) 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
ATE420177T1 (de) 1999-04-16 2009-01-15 Genentech Inc Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
HU230159B1 (hu) 1999-06-08 2015-09-28 Regeneron Pharmaceuticals, Inc. VEGF receptor kimérák alkalmazása vaszkuláris permeabilitással jellemzett szembetegség kezelésére
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
DK1608685T3 (da) 2003-03-28 2007-06-11 Regeneron Pharma VEGF antagonister til behandlingen af diabetes
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
US20040266688A1 (en) 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
AU2004247095A1 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for tumor regression
ITMI20031261A1 (it) 2003-06-20 2004-12-21 Messersi Packaging Srl Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia.
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (en) 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
NZ601544A (en) 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
EP1740168A2 (en) 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
PL1767546T3 (pl) 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
AU2005254058A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
JP2008503481A (ja) 2004-06-18 2008-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 悪性胸膜滲出液の処置のためのｖｅｇｆインヒビターの投与および使用の方法
CN1997386B (zh) 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
AU2005299701B2 (en) 2004-10-21 2011-11-17 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006088650A2 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
CN104804097B (zh) 2014-01-25 2019-02-22 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其用途
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
US20160244504A1 (en) 2016-08-25
US8921316B2 (en) 2014-12-30
US20170360930A1 (en) 2017-12-21
US20210393778A1 (en) 2021-12-23
US11806398B2 (en) 2023-11-07
CA3142945A1 (en) 2006-10-05
ES2633574T3 (es) 2017-09-22
PL1861116T3 (pl) 2016-02-29
US20150079087A1 (en) 2015-03-19
HUE027096T2 (en) 2016-08-29
US20130261056A1 (en) 2013-10-03
KR20080015780A (ko) 2008-02-20
US8110546B2 (en) 2012-02-07
CA2598711C (en) 2018-05-29
HUE034109T2 (en) 2018-01-29
US10406226B2 (en) 2019-09-10
IL227215A (en) 2016-02-29
US9636400B2 (en) 2017-05-02
AU2006229930A1 (en) 2006-10-05
US9416167B2 (en) 2016-08-16
CN102614134B (zh) 2016-09-07
US20210252147A1 (en) 2021-08-19
US20170073407A1 (en) 2017-03-16
US10857231B2 (en) 2020-12-08
US20160175439A1 (en) 2016-06-23
NZ560713A (en) 2010-11-26
DK1861116T3 (en) 2015-11-09
CY1119243T1 (el) 2018-02-14
JP5752671B2 (ja) 2015-07-22
US20210393530A1 (en) 2021-12-23
DK2586459T3 (en) 2017-09-11
US9511140B2 (en) 2016-12-06
US20100279933A1 (en) 2010-11-04
SI2586459T1 (sl) 2017-10-30
US20210252105A1 (en) 2021-08-19
WO2006104852A2 (en) 2006-10-05
WO2006104852A3 (en) 2007-02-01
IL185606A0 (en) 2008-01-06
ZA200708845B (en) 2010-07-28
IL185606A (en) 2013-08-29
US20060217311A1 (en) 2006-09-28
JP5376573B2 (ja) 2013-12-25
EP3195874A1 (en) 2017-07-26
KR101327270B1 (ko) 2013-11-08
PT2586459T (pt) 2017-07-25
US20190388539A1 (en) 2019-12-26
US8710004B2 (en) 2014-04-29
JP2013079270A (ja) 2013-05-02
EP2586459B1 (en) 2017-05-24
PT1861116E (pt) 2015-11-04
EP1861116B1 (en) 2015-09-16
EP1861116A2 (en) 2007-12-05
EP2586459A1 (en) 2013-05-01
AU2006229930C1 (en) 2013-07-25
CN102614134A (zh) 2012-08-01
LT2586459T (lt) 2017-09-25
US20210077624A1 (en) 2021-03-18
CA2995971A1 (en) 2006-10-05
AU2006229930B2 (en) 2010-08-05
JP2008535819A (ja) 2008-09-04
US20120178683A1 (en) 2012-07-12
US20120101035A1 (en) 2012-04-26
HK1116050A1 (en) 2008-12-19
PL2586459T3 (pl) 2017-12-29
CN101141975A (zh) 2008-03-12
SI1861116T1 (sl) 2015-12-31
CA2598711A1 (en) 2006-10-05
US8404638B2 (en) 2013-03-26
CN101141975B (zh) 2012-05-23
CY1116980T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
ES2548238T3 (es) Formulaciones antagonistas de VEGF
AR050353A1 (es) Composicion de anticuerpo her2
ECSP088962A (es) Nuevos herbicidas
CL2012002522A1 (es) Composición farmacéutica que comprende un compuesto inhibidor de dpp iv con un grupo amino o una sal del mismo , un primer diluyente , un segundo diluyente ,un aglutinante , un disgregante y un lubricante, útil en el tratamiento de diabetes mellitus.
ES2513392T3 (es) Materiales biológicos y usos de los mismos
MX2024004337A (es) Composicion farmaceutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t.
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
CL2008003074A1 (es) Anticuerpo anti-tenb2 que comprende uno o mas aminoacidos libres de cisteinas de una secuencia definida; metodo para determinar la presencia de una proteina tenb2 en una muestra sospechosa que contiene la proteina; formulacion farmaceutica que comprende el anticuerpo; compuesto de un conjugado y un farmaco.
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
JP2020513554A (ja) 胃腸管の検出方法、装置およびシステム
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
AR052190A1 (es) Uso de clorantes de cianina para el diagnostico de enfermedades proliferativas
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
EP3351558A3 (en) Material and methods for treating or preventing her-3 associated diseases
EA200701597A1 (ru) Димерные ингибиторы ингибиторов белков апоптоза (iap)
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
PE20081214A1 (es) Anticuerpo especifico prlr y sus usos
UY32609A (es) Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteína
MX2009013293A (es) Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
CL2008003524A1 (es) Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia.
WO2008054600A3 (en) Compositions and methods for biodetection by nucleic acid-templated chemistry
Trusch et al. Cell entry of a host-targeting protein of oomycetes requires gp96
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»